A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis
Latest Information Update: 28 Feb 2025
At a glance
- Drugs LNA 043 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Acronyms ONWARDS
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 24 Feb 2025 Planned End Date changed from 27 May 2025 to 28 May 2025.
- 27 Jan 2025 Planned End Date changed from 25 Oct 2027 to 27 May 2025.
- 13 Aug 2024 Planned primary completion date changed from 7 Oct 2024 to 24 Sep 2024.